Wire · opportunities
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 August 2026 · Fusion42 review
The FDA has granted accelerated approval to Tudriqev, a genetically modified oncolytic viral therapy combined with nivolumab to treat adult patients with unresectable advanced melanoma who are refractory to anti-PD-1 therapy. Clinical trial data showed a 24% response rate with responses lasting a median of nearly 14 months in this difficult-to-treat population.
This Wire brief sits within Fusion42's coverage of Biotech, and 14 sources have reported it between 6 Aug 2026 and 10 Aug 2026.
◆ ◆ The Wire takeaway
FDA approval of Tudriqev changes the treatment game for advanced melanoma resistant to PD-1 blockers, opening a new market for drug developers and suppliers alike. You gain a direct entry point to oncologists seeking next-generation therapies for hard-to-treat patients.
◆ Coverage
14 sources · first reported 6 Aug 2026 · latest 10 Aug 2026
◆ Topics